SCHEMBL25210888

SCHEMBL25210888

CCOC(=O)c1nnc(-c2cc(OC(F)(F)F)ccc2C2CC2)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ GABRG2 P18507 1/20 0.39
▸ GABRB3 P28472 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ POLB P06746 3/20 0.38
▸ CTSA P10619 2/20 0.38
▸ ELANE P08246 2/20 0.38
▸ EPHX2 P34913 2/20 0.37
▸ FAAH O00519 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ NOTUM Q6P988 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30474038 1.00 CA1 (0.42) CA1CA2GABRG2GABRB3GABRA5
SCHEMBL25209422 0.84 CA1 (0.46) CA1CA2GABRG2GABRB3GABRA5
SCHEMBL25212673 0.83 FFAR4 (0.45) CA1CA2GABRG2GABRB3GABRA5
SCHEMBL25248674 0.83 CA1 (0.47) CA1CA2GABRG2GABRB3GABRA5
SCHEMBL30473929 0.83 HTT (0.47) GABRG2GABRB3GABRA5POLBELANE
SCHEMBL25211651 0.83 HTT (0.47) GABRG2GABRB3GABRA5POLBELANE
SCHEMBL30474026 0.81 CA1 (0.43) CA1CA2GABRG2GABRB3GABRA5
SCHEMBL25208574 0.81 CA1 (0.43) CA1CA2GABRG2GABRB3GABRA5
SCHEMBL25242207 0.81 PLAT (0.44) GABRG2GABRB3GABRA5POLBELANE
SCHEMBL30473934 0.81 PLAT (0.44) GABRG2GABRB3GABRA5POLBELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034122-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2025-01-30 — — US disclosed
EP-4441044-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2024-10-09 — — EP disclosed
CN-118302422-A Substituted N-cyanopyrrolidines having activity as USP30 inhibitors 特殊治疗有限公司 2024-07-05 — — CN disclosed
WO-2023099561-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2023-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034122-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS USP30, USP47, USP1 CA1 4332/4885CA2 3464/4885GABRG2 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback